Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Algernon Pharmaceuticals Inc C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by Whalewatcher1on Apr 04, 2023 4:20pm
159 Views
Post# 35379593

Algernon Neuro - Why would anyone invest in it?

Algernon Neuro - Why would anyone invest in it?Algernon Neuro has a $20M pre-money valuation and the almost $2M in debt and trying to raise $10M since beginning of year. Meanwhile Algernon Phamra has $2.4M valuation today and would control 75% of Algernon Neuro. Now the disconnect is that does anyone believe either company will raise the capital? Is it time for new management to step in and save this or do the 2 companies have too much debt (Algernon Pharma with millions now in debt? keep in mind they have an ATM in place and soon as there's a bid they'll likely sell shares to cap any upsize here, desperate times requires desperate measures. And dont bring back Dr. Williams, looks like his new company Marvel Bio also has issues raising capital. They announced plans to riase $1.5M and could only bring in $1M with half from the ex-broker and now CEO Rod Matheson.

Thoughts? 
<< Previous
Bullboard Posts
Next >>